| Property | Value |
|---|
|
?:abstract
|
-
AIMS Dipeptidyl Peptidase-4 (DPP-4), the target of oral antidiabetic drugs DDP-4 inhibitors, has been suggested to be involved in the pathogenesis of coronavirus infections, including COVID-19. It is unclear whether the routine use of DPP-4 inhibitors increases the severity of COVID-19 in people with type 2 diabetes (T2D). Our purpose was to investigate the association between routine use of DPP-4 inhibitors and the severity of COVID-19 infection in a large multicentric study. MATERIAL AND METHODS This study was a secondary analysis of the CORONADO study on 2449 patients with T2D hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs non-users) and were used into multivariable logistic regression models to estimate Average Treatment effect in the Treated as Inverse Probability of Treatment Weighting (IPTW). RESULTS 596 participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs 28.6%, P=0.68). In propensity analysis, the IPTW-adjusted models showed no significant association between use of DPP-4 inhibitors and the primary outcome within day 7 (OR [95%CI]: 0.95 [0.77-1.17]) or day 28 (OR [95%CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death. CONCLUSIONS These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued. This article is protected by copyright. All rights reserved.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
-
Diabetes,_obesity_&_metabolism
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}